首页 Horizon制药(usHZNP)-基本信息

Horizon制药(usHZNP)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:90.6

最高价:92.43

成交量:1046041.0

昨收价:91.0

最低价:90.6

最新价:91.48

行情图标
概要信息

中文名称:Horizon制药


英文名称:Horizon Pharma PLC


简介:Horizon Pharma Public Limited Company是一家专门的制药公司,专营DUEXIS, VIMOVO和RAYOS/LODOTRA


电话:353-1-7722100


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Horizo​​n Therapeutics plc是一家爱尔兰税务注册的制药公司,收购,重塑,重新包装和重新销售销售到美国医疗保健系统的专业药品,美国业务收入占Horizo​​n 2017年全球销售额的97%。 2014年,Horizo​​n实施了税收倒置,将其法定总部迁至爱尔兰,以利用爱尔兰的低税率和有利的公司税制。Horizo​​n Therapeutics Public Limited Company是一家生物制药公司,专注于研究,开发和商业化药物,以满足美国和国际上罕见和风湿性疾病的未满足治疗需求。Horizo​​n Therapeutics孤儿和风湿病药上市药物(商用阶段)包括: KRYSTEXXA,一种治疗不受控制的痛风的药物; RAVICTI,用作成人和儿科患者慢性管理的氮结合剂; PROCYSBI,用于治疗肾病性膀胱病,这是一种罕见且危及生命的代谢紊乱; ACTIMMUNE® (丙型干扰素-1b),治疗慢性肉芽肿病; 延时释放片剂RAYOS®(prednisone),用于治疗多种病症,类风湿性关节炎; BUPHENYL片剂,用于口服;BUPHENYL粉末,用于口服,鼻胃管或胃造口管给药; QUINSAIR,一种抗生素药物左氧氟沙星的配方,用于治疗成人囊性纤维化患者因铜绿假单胞菌引起的慢性肺部感染; 2%的PENNSAID,用于治疗膝关节骨性关节炎的疼痛; DUEXIS® (ibuprofen/famotidine),用于缓解RA和OA的体征和症状,并降低发生上消化道溃疡的风险; VIMOVO® (naproxen/esomeprazole),用于缓解OA,RA和AS的体征和症状,并降低患有NSAID相关性胃溃疡风险的患者发生胃溃疡的风险; MIGERGOT,一种治疗或预防血管性头痛的疗法,如偏头痛和偏头痛变种。Horizo​​n Therapeutics与Lupus Research联盟,Syneos Health, Inc.和HemoShear Therapeutics, LLC签订了合作协议。Horizo​​n Therapeutics公司于美国伊利诺州的第尔非、乔治亚州的罗斯威尔;瑞士的赖纳赫;德国的曼海姆皆设有办事处。Horizo​​n Therapeutics(HZNP)历史百科: 2014年3月,Horizon Pharma以6.6亿美金收购Vidara Therapeutics International; 2014年10月,Horizon Pharma以4500万美金收购Nuvo Research公司在美国的骨关节炎药物Pennsaid的经销权; 2015年3月,Horizon Pharma以11亿美金收购Hyperion Therapeutics; 2016年9月,Horizon Pharma公司宣布以8亿美元收购Raptor Pharmaceutical,将Procysbi和Quinsair加入其稀有药物组合中; 2017年,Horizon宣布有意以1.45亿美元收购River Vision Development Corp,并继续开发teprotumumab; 2019年5月2日,公司股东批准将公司名称更改为Horizon Therapeutics plc。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-30 Karnani (Vikram) Officer Sell 13111 25.02
2019-06-11 Curtis (Geoffrey M) Officer Gift 1265 --
2019-06-09 McHugh (Miles W) Officer Buy 3333 --
2019-06-09 McHugh (Miles W) Officer Sell 1477 23.36
2019-06-09 Kent (Jeffrey) Officer Sell 2215 23.36
2019-06-09 Kent (Jeffrey) Officer Buy 5000 --
2019-06-04 Kent (Jeffrey) Officer Sell 1250 24.64
2019-05-02 Grey (Michael G.) Director Buy 15320 --
2019-05-02 Witz (Pascale) Director Buy 15320 --
2019-05-02 Shannon (James Samuel) Director Sell 6014 26.54
2019-05-02 Shannon (James Samuel) Director Buy 15320 --
2019-05-02 Santini (Gino) Director Buy 15320 --
2019-05-02 Santini (Gino) Director Sell 6014 26.54
2019-05-02 Witz (Pascale) Director Sell 6014 26.54
2019-05-02 Daniel (William F) Director Sell 4132 26.54
2019-05-02 Daniel (William F) Director Buy 15320 --
2019-05-02 Himawan (Jeffrey) Director Buy 15320 --
2019-05-02 Himawan (Jeffrey) Director Sell 4132 26.54
2019-05-02 Grey (Michael G.) Director Sell 4132 26.54
2019-05-01 Pauli (Ronald Edwin) Director Buy 15320 --
2019-05-01 Pauli (Ronald Edwin) Director Sell 6014 25.99
2019-04-07 Curtis (Geoffrey M) Officer Buy 7000 --
2019-04-07 Curtis (Geoffrey M) Officer Sell 3101 27.16
2019-03-22 Karnani (Vikram) Officer Buy 9500 --
2019-03-22 McHugh (Miles W) Officer Sell 4209 26.84

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments N A 2345672 1.27% 16374 0.70% 2019-03-31
Fidelity Management & Research Company 5297840 2.87% 1970082 59.20% 2019-07-31
BlackRock Fund Advisors 6054129 3.27% -5150572 -45.97% 2019-07-31
Deerfield Management Co 6462634 3.50% -363085 -5.32% 2019-03-31
Paulson & Company Inc 6670700 3.61% -500000 -6.97% 2019-03-31
William Blair Investment Management, LLC 6942357 3.76% 269565 4.04% 2019-03-31
Renaissance Technologies Corp 7857775 4.25% 1791500 29.53% 2019-03-31
Scopia Management Inc 8159184 4.42% -2566458 -23.93% 2019-03-31
Vanguard Group Inc 16881219 9.14% 1515341 9.86% 2019-03-31
FMR Inc 5205217 2.82% 3242071 165.15% 2019-03-31
Fidelity Management and Research Company 5165617 2.80% 3202471 163.13% 2019-03-31
Vanguard Investments Australia Ltd 5069569 2.74% 5001 0.10% 2019-07-31
J.P. Morgan Investment Management, Inc. 2351518 1.27% 536027 29.53% 2019-07-31
Eagle Asset Management, Inc. 2697477 1.46% -7439 -0.28% 2019-03-31
Northern Trust Investments Inc 3483559 1.88% -126069 -3.49% 2019-07-31
State Street Corporation 3798424 2.06% 197969 5.50% 2019-03-31
venBio Select Advisor LLC 4000000 2.17% -350000 -8.05% 2019-03-31
Dimensional Fund Advisors LP 4034176 2.18% -44181 -1.08% 2019-07-31
D. E. Shaw & Co LP 4401979 2.38% 1032471 30.64% 2019-03-31
Dimensional Fund Advisors, Inc. 5000270 2.71% -140297 -2.73% 2019-03-31
Northern Trust Corp 2345672 1.27% 16374 0.70% 2019-03-31
BlackRock Inc 13896831 7.52% 266698 1.96% 2018-12-31
BlackRock Asset Management Canada Ltd 4165884 2.25% -67 -- 2019-05-31
Geode Capital Management, LLC 3870914 2.10% 2093799 117.82% 2018-12-31
JPMorgan Chase & Co 5060893 2.75% -335331 -6.21% 2018-09-30
Glenmede Trust Co NA 2451701 1.45% -828766 -25.26% 2018-09-30
Brandywine Global Investment Mgmt LLC 2478198 1.46% -444512 -15.21% 2018-09-30
Teachers Advisors LLC 2416716 1.44% 1224842 102.77% 2018-09-30
Bank of America Corporation 2315613 1.38% 617595 36.37% 2018-06-30
BlackRock Institutional Trust Company NA 4609786 2.75% 93763 2.08% 2018-06-30
JP Morgan Asset Management (UK) Ltd 2575888 1.54% 486300 23.27% 2018-06-30
State Street Corp 3838449 2.30% 64156 1.70% 2018-06-30
William Blair Investment Mgmt 3005155 1.80% 94820 3.26% 2018-07-31
J P Morgan Asset Management (UK) Ltd 2575888 1.55% 486300 23.27% 2018-06-30
J.P. Morgan Investment Management Inc 2355661 1.41% 1052855 80.81% 2018-06-30
Columbia Mangmt Investment Advisers, LLC 2214952 1.33% -426542 -16.15% 2018-06-30
Merrill Lynch & Co Inc 1833942 1.10% 524347 40.04% 2018-06-30
Rothschild Asset Management Inc 1681191 1.01% -14369 -0.85% 2018-06-30
Rhenman Partners Asset Management AB 1632212 0.98% -375000 -18.68% 2018-06-30
NORGES BANK 2158675 1.31% -80962 -3.61% 2017-12-31
Broadfin Capital, LLC 3097964 1.89% -962883 -23.71% 2017-09-30
Kingdon Capital Management LLC 12748199 7.89% 7971970 166.91% 2016-12-31
Point72 Asset Management, L.P. 2809500 1.71% -844000 -23.10% 2017-09-30
Goldman, Sachs & Co. 2143152 1.31% 1334595 165.06% 2017-06-30
Citigroup Inc 2583851 1.58% 2425818 1535.01% 2017-06-30
Invesco PowerShares Capital Mgmt LLC 1988004 1.22% 1900128 2162.28% 2017-06-30
Lone Pine Capital LLC 15600988 9.77% 7247320 86.76% 2015-12-31
Healthcor Management LP 4250000 2.64% 4250000 -- 2016-09-30
Janus Capital Management LLC 3815813 2.37% -225931 -5.59% 2016-09-30
Consonance Capital Management LP 3698903 2.29% 3698903 -- 2016-09-30
TimesSquare Capital Management, LLC 2408475 1.49% -1450815 -37.59% 2016-09-30
Hodges Capital Management Inc 2087636 1.29% -100358 -4.59% 2016-09-30
Scale Management LLC 1710451 1.06% -- -- 2016-09-30
Fiera Capital Corporation 1704056 1.06% -50155 -2.86% 2016-09-30
Vanguard Group Inc. 8595909 9.00% 170370916 -- 1999-11-30
Deerfield Management Co. 12259875 9.00% 242990722 0.10% 1999-11-30
Fidelity and its affiliates 22546090 9.00% 446863504 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
TIAA-CREF Quant Small-Cap Equity Fund 834700 0.45% -13300 -1.57% 2019-05-31
Vanguard Total Stock Market Index Fund 5028000 2.72% 923 0.02% 2019-06-30
Vanguard Small Cap Index 4723129 2.55% -21164 -0.45% 2019-06-30
Vanguard Small Cap Growth Index Fund 2712341 1.47% 19570 0.73% 2019-06-30
Vanguard Extended Market Index Fund 2538191 1.37% 14227 0.56% 2019-06-30
DFA US Small Cap Portfolio 2251975 1.22% -31726 -1.39% 2019-05-31
Columbia Acorn Fund 1861457 1.01% -- -- 2019-06-30
Polar Capital Healthcare Opps Fund 1848446 1.00% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 1825095 0.99% 18265 1.01% 2019-07-30
Carillon Eagle Small Cap Growth Fund 1805886 0.98% -- -- 2019-06-30
William Blair Small-Mid Cap Growth Fund 1574146 0.85% 19100 1.23% 2019-06-30
Rhenman Healthcare Eq L/S 850000 0.46% -89973 -9.57% 2019-04-30
Fidelity 883350 0.48% -- -- 2019-06-30
William Blair Small-Mid Cap Growth CIT 930502 0.50% -5430 -0.58% 2019-06-30
PGIM Jennison Small Company Fund 1179815 0.64% -30818 -2.55% 2019-06-30
JPMorgan Small Cap Growth Fund 1442709 0.78% 40594 2.90% 2019-06-30
Glenmede Small Cap Equity Tr 1540179 0.83% -318446 -17.13% 2019-06-30
Glenmede Small Cap Equity Portfolio 1540179 0.83% -318446 -17.13% 2019-06-30
iShares Russell 2000 ETF 3708036 2.01% 8196 0.22% 2019-06-27
iShares Russell 2000 Growth ETF 1529572 0.83% -1681 -0.11% 2019-06-27
iShares US Small Cap ETF (CAD-Hedged) 3663641 1.98% -6147 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 4751388 2.57% 35965 0.76% 2019-04-30
iShares Russell 2000 Value ETF 1850596 1.09% -3051 -0.16% 2018-06-21
William Blair SICAV US Sm-Md Cap Gr Fd 605145 0.36% 14700 2.49% 2019-02-28
Invesco Dynamic Pharmaceuticals ETF 663401 0.40% -- -- 2019-01-31
William Blair Small Cap Growth Fund 721500 0.43% 22170 3.17% 2018-10-31
American Beacon Large Cap Value Fund 841292 0.50% -- -- 2018-09-30
AB Short Duration High Yld Port 1621187 0.97% 1621187 -- 2017-08-31
Columbia Small Cap Value Fund II 810800 0.48% -214200 -20.90% 2018-09-30
iShares Nasdaq Biotechnology 1872755 1.11% -3564 -0.19% 2018-09-12
Schwab US Small-Cap ETF 456532 0.27% -- -- 2018-09-13
SPDR 563339 0.33% -- -- 2018-09-13
William Blair Small Cap Growth I 663890 0.40% 22320 3.48% 2018-07-31
Fidelity Spartan 761874 0.46% -- -- 2018-07-31
TIAA-CREF Small-Cap Equity Instl 855600 0.51% -- -- 2018-07-31
PowerShares Dynamic Pharmaceuticals ETF 778044 0.45% -- -- 2018-09-13
Vanguard Total Stock Mkt Idx 4125425 2.48% 4646 0.11% 2018-07-31
Glenmede Small Cap Equity Adv 2936438 1.76% 18884 0.65% 2018-06-30
DFA US Small Cap I 2383195 1.43% -- -- 2018-07-31
Vanguard Small Cap Growth Index Inv 2372943 1.42% 36713 1.57% 2018-07-31
William Blair Small-Mid Cap Gr I 2341265 1.41% 72500 3.20% 2018-07-31
Vanguard Extended Market Idx Inv 2181956 1.31% 17567 0.81% 2018-07-31
iShares Russell 2000 Growth 1599326 0.95% -1542 -0.10% 2018-09-12
American Beacon Lg Cap Value Inst 924492 0.55% -27200 -2.86% 2018-07-31
Columbia Small Cap Value Fund II A 1025000 0.62% -75000 -6.82% 2018-07-31
JPMorgan Small Cap Growth A 1240813 0.74% 93314 8.13% 2018-07-31
William Blair Small-Mid Cap Growth Collective Investment Fund 1422946 0.85% 57950 4.25% 2018-07-31
Eagle Small Cap Growth A 1805886 1.08% 1805886 -- 2018-06-30
DFA Tax-Managed US Targeted Value 544742 0.33% -- -- 2018-06-30
DFA US Targeted Value I 633151 0.38% -117624 -15.67% 2018-05-31
Columbia Small/Mid Cap Value A 490000 0.30% -- -- 2018-05-31
iShares Russell 2000 Value 1579057 1.04% 2034 0.13% 2018-06-14
JHFunds2 Small Company Gr NAV 497305 0.30% -3912 -0.78% 2018-03-31
DFA US Core Equity 2 I 491870 0.30% -16600 -3.26% 2018-03-31
iShares US Pharmaceuticals 453448 0.30% -- -- 2018-03-05
Janus Global Life Sciences D 1899042 1.18% -157810 -7.67% 2016-12-31
Hodges Small Cap Retail 1450000 0.90% -50000 -3.33% 2016-09-30
RI CBF AllianceBern Discovery Val RZ 1047730 0.65% 340740 48.20% 2016-12-31
JPMorgan Mid Cap Growth Sel 1010300 0.63% 166100 19.68% 2016-12-31
Fidelity Advisor 1004191 0.62% -248728 -19.85% 2016-12-31
Fidelity® Select Health Care Portfolio 2380000 1.50% -- -- 2015-09-30
Fidelity® Diversified International Fund 2241000 1.40% -13000 -0.60% 2015-09-30
Fidelity Advisor® Biotechnology Fund 1753137 1.10% 7199 0.40% 2015-09-30
Fidelity VIP Contrafund Portfolio 1448700 0.90% -- -- 2015-09-30
Fidelity® Balanced Fund 1414800 0.90% -- -- 2015-09-30
Janus Global Life Sciences Fund 1396018 0.90% 823543 143.90% 2015-09-30
Hodges Small Cap Fund 1350000 0.80% -125000 -8.50% 2015-09-30
American Century Heritage Fund 991780 0.60% 991780 -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 8813602 5.50% 29500 0.30% 2015-09-30

Gino Santini Currently, Gino Santini is Chairman for AMAG Pharmaceuticals, Inc. He is also on the board of 8 other companies. In his past career he was Senior VP-Business Development & Strategy at Eli Lilly & Co. and General Manager for Eli Lilly y CIA de M�0�1�0�8xico SA de CV (a subsidiary of Eli Lilly & Co.), Chairman at National Pharmaceutical Council and Chairman for Noble of Indiana. Gino Santini received an undergraduate degree from the University of Bologna and an MBA from the University of Rochester Simon Business School.
H. Thomas Watkins H. Thomas Watkins is Chairman for Vanda Pharmaceuticals, Inc. He is also on the board of 6 other companies. In the past Mr. Watkins occupied the position of President for TAP Pharmaceutical Products, Inc., Vice President of Abbott Laboratories, President, Chief Executive Officer & Director at Human Genome Sciences, Inc. and Chairman for Biotechnology Innovation Organization. Mr. Watkins received an undergraduate degree from The College of William & Mary and an MBA from The University of Chicago Booth School of Business.
Timothy P. Walbert Mr. Timothy P. Walbert is a President & Chief Executive Officer at Hyperion Therapeutics, Inc., a Chairman at Egalet Corp., a Chairman, President & Chief Executive Officer at Horizon Pharma USA, Inc., a Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc, a Member at Illinois Innovation Council and a Member at The National Organization for Rare Disorders, Inc. He is on the Board of Directors at Exicure, Inc., Horizon Pharmaceutical LLC, World Business Chicago, Pharmaceutical Research & Manufacturers of America, Biotechnology Innovation Organization, Illinois Biotechnology Industry Organization, Chicagonext, MATTER Chicago and The Arthritis Foundation. Mr. Walbert was previously employed as an Independent Director by Sucampo Pharmaceuticals, Inc., an Independent Director by Raptor Pharmaceutical Corp., an Independent Director by XOMA Corp., a Chairman, President & Chief Executive Officer by Horizon Pharma, Inc., a President, Chief Executive Officer & Director by IDM Pharma, Inc., an Executive Vice President-Commercial Operations by NeoPharm, Inc., a Divisional VP & General Manager-Immunology by Abbott Laboratories, a Manager-Market Integration by Merck & Co., Inc., a Product Manager-Arthrotec & Cytotec by G.D. Searle & Co., Inc., a Territory Manager by American Home Products Corp., a President & Chief Executive Officer by Horizon Therapeutics, Inc., and a Trustee by Muhlenberg College. He also served on the board at Raptor Pharmaceuticals Corp. and Celebrex North America. He received his undergraduate degree from Muhlenberg College.
Jeff Himawan Founder of Seed-One Ventures LLC and Elusys Therapeutics, Inc., Jeff Himawan occupies the position of Chairman of MediciNova, Inc. and Managing Director at Essex Woodlands Management, Inc., Managing Director at Essex Woodlands Health Ventures LP (a subsidiary of Essex Woodlands Management, Inc.). Dr. Himawan is also on the board of Light Sciences Oncology, Inc. (former Chairman), Horizon Therapeutics Plc, Horizon Pharma USA, Inc. and Catalyst Biosciences, Inc. and Managing Director at Essex Woodlands Health Ventures LP. He previously was Managing Director at Seed-One Ventures LLC and Principal at Genzyme Corp. Jeff Himawan received an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Harvard University.
Pascale Witz Pascale Witz founded PWH Advisors. Presently, she is President & Chief Executive Officer at this company. She is also on the board of PerkinElmer, Inc. (United States), Horizon Therapeutics Plc, Regulus Therapeutics, Inc. and French-American Foundation-France. In her past career she occupied the position of EVP-Diabetes & Global Heart Disease at Sanofi, President & CEO-Medical Diagnostics at GE Healthcare Ltd. and Marketing Manager at Becton Dickinson France SAS. Ms. Witz received a graduate degree from Institut National des Sciences Appliqu�0�1�0�8es de Lyon and an MBA from INSEAD.
Susan Mahony Dr. Susan Mahony is an Independent Director at Zymeworks, Inc. and an Independent Director at Assembly Biosciences, Inc. She is on the Board of Directors at Horizon Therapeutics Plc, Zymeworks, Inc., Vifor Pharma AG, Assembly Biosciences, Inc. and Park Tudor School. Dr. Mahony was previously employed as a President & Senior Vice President by Lilly Oncology, a General Manager by Eli Lilly Canada, Inc., a Senior Vice President by Eli Lilly & Co., a Principal by Bristol-Myers Squibb Co., a Principal by Amgen, Inc., and a Principal by Schering-Plough Corp. She also served on the board at United Way of Central Indiana, Inc. She received her undergraduate degree from the University of Aston, an MBA from London Business School and a doctorate degree from the University of Aston.
Barry J. Moze Founder of Review Services, Inc. and Asset Management Group, Inc., Barry J. Moze is on the board of Palermo Villa, Inc. and Chief Administrative Officer & Executive VP at Horizon Therapeutics Plc. In the past Mr. Moze was President of Review Services, Inc., President for Asset Management Group, Inc. and Partner & Owner at Crystal Clear Communications, Inc.
Jeffrey W. Sherman Currently, Jeffrey W. Sherman occupies the position of Chief Medical Officer & Executive VP-Research at Horizon Pharma Plc and Chief Medical Officer & EVP-Regulatory Affairs at Horizon Pharma USA, Inc. and Chief Marketing Officer & Executive Vice President at Hyperion Therapeutics, Inc. (both are subsidiaries of Horizon Pharma Plc). Dr. Sherman is also on the board of Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma Plc. Dr. Sherman previously held the position of Member of American Board of Internal Medicine, Vice President-Clinical Science at Takeda Global Research & Development Center, Inc., Chief Medical Officer, SVP-Research & Development at IDM Pharma, Inc., Chief Medical Officer & EVP-Regulatory Affairs at Horizon Pharma, Inc., Chief Medical Officer & Executive Vice President at NeoPharm, Inc., Chief Medical Officer & Executive Vice President at Horizon Therapeutics, Inc., Head-Oncology Global Medical Operations at Pharmacia Corp., President & Director at Drug Information Association, Member of The National Board of Medical Examiners, Inc. and Research Associate at Howard Hughes Medical Institute, Inc. Dr. Sherman received a doctorate from Chicago Medical School and an undergraduate degree from Lake Forest College.
William Francis Daniel Mr. William F. Daniel is a Non-Executive Chairman at Malin Corp. Plc and an Independent Director at Horizon Therapeutics Plc. He is on the Board of Directors at Horizon Therapeutics Plc and Elan Pharma International Ltd. Mr. Daniel was previously employed as a President & Director by Institute of Directors In Ireland, a Secretary & Executive Vice President by Elan Corp. Plc, a Financial Director by Xtravision Plc, a Head-Finance by An Post Group, and a President by Financial Executives Association. He also served on the board at Alkermes Plc. He received his undergraduate degree from the University College Dublin.
Michael G. Grey Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham.
Jeff Himawan Founder of Seed-One Ventures LLC and Elusys Therapeutics, Inc., Jeff Himawan occupies the position of Chairman of MediciNova, Inc. and Managing Director at Essex Woodlands Management, Inc., Managing Director at Essex Woodlands Health Ventures LP (a subsidiary of Essex Woodlands Management, Inc.). Dr. Himawan is also on the board of Light Sciences Oncology, Inc. (former Chairman), Horizon Therapeutics Plc, Horizon Pharma USA, Inc. and Catalyst Biosciences, Inc. and Managing Director at Essex Woodlands Health Ventures LP. He previously was Managing Director at Seed-One Ventures LLC and Principal at Genzyme Corp. Jeff Himawan received an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Harvard University.
Miles W. McHugh Miles W. McHugh holds the position of Chief Accounting Officer & Senior Vice President at Horizon Pharma Plc. In his past career he was Chief Financial Officer & Executive Vice President for R.R. Donnelley & Sons Co. and Chief Financial Officer & Vice President at RR Donnelley Logistics Services Worldwide, Inc. (a subsidiary of R.R. Donnelley & Sons Co.), Chief Accounting Officer & Senior Vice President of R1 RCM, Inc., Chief Accounting Officer, Director & Senior VP at Horizon Pharma Plc, Chief Financial Officer & Secretary for Exopack Holding Corp. and Controller for DPL, Inc. Miles W. McHugh received an MBA from The University of Chicago Booth School of Business and an undergraduate degree from the University of Illinois.
Miles W. McHugh Miles W. McHugh holds the position of Chief Accounting Officer & Senior Vice President at Horizon Pharma Plc. In his past career he was Chief Financial Officer & Executive Vice President for R.R. Donnelley & Sons Co. and Chief Financial Officer & Vice President at RR Donnelley Logistics Services Worldwide, Inc. (a subsidiary of R.R. Donnelley & Sons Co.), Chief Accounting Officer & Senior Vice President of R1 RCM, Inc., Chief Accounting Officer, Director & Senior VP at Horizon Pharma Plc, Chief Financial Officer & Secretary for Exopack Holding Corp. and Controller for DPL, Inc. Miles W. McHugh received an MBA from The University of Chicago Booth School of Business and an undergraduate degree from the University of Illinois.
Paul W. Hoelscher Currently, Paul W. Hoelscher occupies the position of Chief Financial Officer & Executive Vice President at Horizon Therapeutics Plc and Chief Financial Officer, Director & Executive VP at Horizon Pharmaceutical LLC and Chief Financial Officer & Secretary at Hyperion Therapeutics, Inc. (both are subsidiaries of Horizon Therapeutics Plc). Paul W. Hoelscher is also Trustee-Illinois Chapter at The Leukemia & Lymphoma Society, Inc. In the past Mr. Hoelscher occupied the position of Chief Financial Officer of Horizon Pharma, Inc., Vice President-Finance at Alberto-Culver LLC, Senior Vice President-Finance & Treasury at OfficeMax, Inc. and Vice President & Controller of Alberto-Culver LLC. He received an undergraduate degree from the University of Illinois.
David A. Happel Mr. David A. Happel is Executive Vice President-Orphan Business Unit at Horizon Pharma Plc and Chief Commercial Officer at Horizon Pharmaceutical LLC. He is on the Board of Directors at Boomer Esiason Foundation. Mr. Happel was previously employed as Vice President-Global Sales & Marketing by Dynavax Technologies Corp., Chief Commercial Officer & EVP by Aerovance, Inc., Vice President-Pulmonology by Chiron Corp., Senior Director-Pulmonary Business Unit by InterMune, Inc., Director-Global Marketing by Warner-Lambert Co., a Principal by Parke, Davis & Co. LLC, and a Principal by Pfizer Inc. He received his undergraduate degree from Indiana University and an MBA from Indiana State University.
David George Kelly David George Kelly holds the position of Secretary & Executive VP, MD-Ireland at Horizon Pharma Plc. He is also on the board of Iterum Therapeutics Plc and Member of The Institute of Chartered Accountants in Ireland. In his past career he held the position of Chief Financial Officer of Warner Chilcott Plc, Chief Financial Officer at HZNP USA LLC, CFO, Secretary & Head-Investor Relations at AGI Therapeutics Plc, Principal at KPMG LLP and Principal at Elan Corp. Plc. David George Kelly received an undergraduate degree from Trinity College Dublin.
Robert F. Carey Robert F. Carey is Chief Business Officer & Executive Vice President at Horizon Therapeutics Plc and Chief Business Officer & Executive Vice President at Hyperion Therapeutics, Inc. and on the board of 6 other companies. He previously held the position of Managing Director at Dresdner Kleinwort Wasserstein, Managing Director at Vector Securities International, Inc., Principal at Shearson Lehman Hutton, Inc., Principal at Ernst & Whinney, Chief Business Officer & Executive Vice President at Horizon Pharma, Inc. and Managing Director at JMP Securities LLC. Mr. Carey received an undergraduate degree from the University of Notre Dame.
Michael A. DesJardin Presently, Michael A. DesJardin occupies the position of Executive Vice President-Technical Operations at Horizon Pharma Plc and Senior Vice President-Technical Operations at Horizon Pharmaceutical LLC (a subsidiary of Horizon Pharma Plc). He is also Senior Vice President-Technical Operations at Horizon Pharmaceutical LLC. In his past career Mr. DesJardin held the position of Senior Vice President-Product Development at Jazz Pharmaceuticals Plc and Executive Director-Implant Research & Development at ALZA Corp. Mr. DesJardin received an undergraduate degree from the University of California, Berkeley.
James Samuel Shannon Dr. James S. Shannon, MD, is an Independent Director at Horizon Therapeutics Plc, a Member-Supervisory Board at ProQR Therapeutics NV, an Independent Director at MannKind Corp. and a Member at The Royal College of Physicians. He is on the Board of Directors at Horizon Therapeutics Plc, ProQR Therapeutics NV, Impatients N.V., Immodulon Therapeutics Ltd. and MannKind Corp. Dr. Shannon was previously employed as a Chief Medical Officer by GlaxoSmithKline Plc, a Non-Executive Director by Circassia Ltd., a Member-Supervisory Board by Crucell NV, an Independent Director by MannKind Corp., an Independent Director by Endocyte, Inc., a President, Chief Executive Officer & Director by Costes Pharmaceuticals, Inc., a Global Head-Drug Development by Novartis Pharma AG, a Head-Drug Regulatory Affairs by Sandoz Ltd., and a Senior Vice President-Clinical Development by Sterling Winthrop, Inc. He also served on the board at Biotie Therapies Oyj, Arch Therapeutics, Inc. /Old/, ViiV Healthcare Ltd. and Xanodyne Pharmaceuticals, Inc. He received his undergraduate degree from Queen's University of Belfast, a graduate degree from Queen's University of Belfast and a doctorate degree from Queen's University of Belfast.
Amy Grahn Amy Grahn is Senior VP-Global Clinical Development & Operations at Horizon Pharma Plc. In her past career she held the position of Vice President-Clinical Operations at MedGenesis Therapeutix, Inc., Principal at Abbott Laboratories, Senior VP-Clinical Development & Operations at Horizon Pharma, Inc., Vice President-Clinical Operations at Horizon Therapeutics, Inc., Principal at Takeda Pharmaceuticals U.S.A., Inc. and Vice President-Clinical Operations at NeoPharm, Inc. Ms. Grahn received a graduate degree from Illinois Institute of Technology and an undergraduate degree from Knox College.
Robert W. Metz Currently, Robert W. Metz occupies the position of Senior VP-Business Operations & Government Affairs at Horizon Pharma Plc. In the past he occupied the position of SVP-Business Operations & Human Resources at Horizon Pharma, Inc., Vice President-Commercial Operations at IDM Pharma, Inc., Vice President-Business Operations at Horizon Therapeutics, Inc., Principal at Reliable Biopharmaceutical Corp., Principal at MedPointe, Inc. and Principal at NeoPharm, Inc. Mr. Metz received an undergraduate degree from Marietta College.
Eric B. Mosbrooker Eric B. Mosbrooker is on the board of National Pharmaceutical Council and Chief Commercial Officer & Senior Vice President at Audentes Therapeutics, Inc. and SVP-Orphan Business Unit at Horizon Pharma Plc. He received an undergraduate degree from the University of Wisconsin.
Brian K. Beeler Brian K. Beeler occupies the position of Executive Vice President & General Counsel of Horizon Pharma Plc. Mr. Beeler previously occupied the position of Senior Counsel at TAP Pharmaceutical Products, Inc., Chief Compliance Officer & Vice President at Horizon Pharma, Inc., Associate General Counsel at Fenwal, Inc., Senior Counsel at Takeda Pharmaceuticals U.S.A., Inc. and Chief Compliance Officer at SCHWARZ PHARMA, Inc. Brian K. Beeler received an undergraduate degree from Purdue University, an MBA from Kellogg School of Management and a graduate degree from Indiana University Maurer School of Law.
Paul W. Hoelscher Currently, Paul W. Hoelscher occupies the position of Chief Financial Officer & Executive Vice President at Horizon Therapeutics Plc and Chief Financial Officer, Director & Executive VP at Horizon Pharmaceutical LLC and Chief Financial Officer & Secretary at Hyperion Therapeutics, Inc. (both are subsidiaries of Horizon Therapeutics Plc). Paul W. Hoelscher is also Trustee-Illinois Chapter at The Leukemia & Lymphoma Society, Inc. In the past Mr. Hoelscher occupied the position of Chief Financial Officer of Horizon Pharma, Inc., Vice President-Finance at Alberto-Culver LLC, Senior Vice President-Finance & Treasury at OfficeMax, Inc. and Vice President & Controller of Alberto-Culver LLC. He received an undergraduate degree from the University of Illinois.
Tim Ayers Currently, Tim Ayers holds the position of Chief Compliance Officer & Vice President at Horizon Pharma Plc. Mr. Ayers received a graduate degree and an undergraduate degree from Georgetown University and a graduate degree from Columbia University.
Marilyn Vetter Presently, Marilyn Vetter holds the position of Vice President-Government & Public Affairs at Horizon Pharma Plc. She is also on the board of Pheasants Forever, Inc. Ms. Vetter received a graduate degree and an undergraduate degree from the University of North Dakota.
Vikram Karnani Vikram Karnani is Chief Commercial Officer & Executive VP of Horizon Pharma Plc.
Tina Ventura Presently, Tina Ventura occupies the position of Senior Vice President-Investor Relations at Horizon Pharma Plc.
Irina P. Konstantinovsky Presently, Irina P. Konstantinovsky occupies the position of Chief Human Resources Officer & Executive VP for Horizon Therapeutics Plc. Ms. Konstantinovsky is also on the board of The Human Resources Management Association of Chicago and YWCA of Metropolitan Chicago. In the past Ms. Konstantinovsky was Vice President-Global Talent at Baxter International, Inc., Director & Senior Partner at Willis Towers Watson (New York) and Chief Human Resource Officer at Capital BlueCross, Inc. Ms. Konstantinovsky received a graduate degree from Cornell University and an undergraduate degree from Universidad de Buenos Aires.
Shao-Lee Lin Presently, Shao-Lee Lin is Chief Scientific Officer for Horizon Therapeutics Plc. She is also on the board of Principia Biopharma, Inc. In her past career she occupied the position of Vice President at AbbVie, Inc. and VP-Inflammation & Respiratory Development at Gilead Sciences, Inc. Dr. Lin received a doctorate from The Johns Hopkins University School of Medicine and an undergraduate degree from Rice University.
Jeffrey D. Kent Currently, Jeffrey D. Kent occupies the position of SVP & Head-Medical Affairs & Outcomes Research at Horizon Pharma Plc. He previously held the position of Global Director at Pfizer Inc., Senior Vice President -Medical Affairs at Astellas Pharma US, Inc., Head-Medical Affairs at Abbott Laboratories, Inc. and Associate Medical Director at Evanston Hospital Corp. He received an undergraduate degree from Franklin & Marshall College and a doctorate from Thomas Jefferson University.
Anne Marie Dempsey Presently, Anne Marie Dempsey is Secretary at Horizon Pharma Plc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐